Angion Biomedica Corp. (ANGN) Stock

About Angion Biomedica Corp.

Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.

Angion Biomedica Corp. is headquartered in US.

Angion Biomedica Corp. (ANGN) stock trades at $1.00 with a market capitalization of $30.11M. The stock is valued at a price-to-earnings (P/E) ratio of -0.42, price-to-book of -12.67, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.00 and $20.40, and currently trades 95.1% below its 52-week high.

On profitability, Angion Biomedica Corp. generates a return on equity (ROE) of -2000.00%, return on capital employed of -243.08%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.angion.com